Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus 6 months

Bookmark and Share
Published: 9 May 2019
Views: 590
Prof John Marshall - Georgetown University Hospital, Washington D.C., USA

Prof John Marshall speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the treatment of stage III colon cancer after surgery.

He describes the adjuvant use of fluorouracil and oxaliplatin in patients with colorectal cancer.

Prof Marshall also discusses the evidence that support the use of these drugs for 3 months of therapy versus 6 months.

In terms of impact, he believes this data gives oncologists a new standard to use to optimise and personalise treatment.